Clinical Trials in Richmond Hill, Canada
1 recruiting
Showing 1–20 of 26 trials
Recruiting
Phase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Incyte Corporation40 enrolled27 locationsNCT07213973
Recruiting
Phase 2
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Janssen Research & Development, LLC180 enrolled56 locationsNCT07230860
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled318 locationsNCT06855498
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled357 locationsNCT07116967
Recruiting
Not Applicable
Platform of Randomized Adaptive Clinical Trials in Critical Illness
Respiratory InsufficiencyMechanical Ventilation Pressure HighExtracorporeal Membrane Oxygenation Complication
University Health Network, Toronto6,250 enrolled89 locationsNCT05440851
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Bristol-Myers Squibb366 enrolled120 locationsNCT06979453
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Colitis Ulcerative
Sanofi204 enrolled115 locationsNCT06867094
Recruiting
Not Applicable
Modifying PEST for Psoriatic Arthritis Screening
Psoriatic ArthritisPlaque Psoriasis
Novartis Pharmaceuticals502 enrolled21 locationsNCT06382051
Recruiting
Phase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
VitiligoNon-Segmental Vitiligo (NSV)
Eli Lilly and Company60 enrolled35 locationsNCT07533019
Recruiting
Phase 2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled55 locationsNCT07105488
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled101 locationsNCT06959225
Recruiting
Not Applicable
Type 1 Diabetes Virtual Self-management Education and Support
Type1diabetes
Unity Health Toronto580 enrolled9 locationsNCT05756829
Recruiting
Phase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia Areata
AbbVie1,500 enrolled268 locationsNCT06012240
Recruiting
Phase 3
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Real-world Secukinumab Outcomes in Canadian HS Patients
Hidradenitis Suppurativa
Novartis Pharmaceuticals142 enrolled11 locationsNCT07282015
Recruiting
Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 2Phase 3
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Bluefin Biomedicine, Inc.210 enrolled33 locationsNCT07287644
Recruiting
Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
AbbVie1,280 enrolled279 locationsNCT06468228
Recruiting
Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Hidradenitis Suppurativa
Novartis Pharmaceuticals555 enrolled145 locationsNCT06799000